- Open Access
Hydrogen inhalation ameliorates ventilator-induced lung injury
Critical Carevolume 14, Article number: R234 (2010)
Mechanical ventilation (MV) can provoke oxidative stress and an inflammatory response, and subsequently cause ventilator-induced lung injury (VILI), a major cause of mortality and morbidity of patients in the intensive care unit. Inhaled hydrogen can act as an antioxidant and may be useful as a novel therapeutic gas. We hypothesized that, owing to its antioxidant and anti-inflammatory properties, inhaled hydrogen therapy could ameliorate VILI.
VILI was generated in male C57BL6 mice by performing a tracheostomy and placing the mice on a mechanical ventilator (tidal volume of 30 ml/kg without positive end-expiratory pressure, FiO2 0.21). The mice were randomly assigned to treatment groups and subjected to VILI with delivery of either 2% nitrogen or 2% hydrogen in air. Sham animals were given same gas treatments for two hours (n = 8 for each group). The effects of VILI induced by less invasive and longer exposure to MV (tidal volume of 10 ml/kg, 5 hours, FiO2 0.21) were also investigated (n = 6 for each group). Lung injury score, wet/dry ratio, arterial oxygen tension, oxidative injury, and expression of pro-inflammatory mediators and apoptotic genes were assessed at the endpoint of two hours using the high-tidal volume protocol. Gas exchange and apoptosis were assessed at the endpoint of five hours using the low-tidal volume protocol.
Ventilation (30 ml/kg) with 2% nitrogen in air for 2 hours resulted in deterioration of lung function, increased lung edema, and infiltration of inflammatory cells. In contrast, ventilation with 2% hydrogen in air significantly ameliorated these acute lung injuries. Hydrogen treatment significantly inhibited upregulation of the mRNAs for pro-inflammatory mediators and induced antiapoptotic genes. In the lungs treated with hydrogen, there was less malondialdehyde compared with lungs treated with nitrogen. Similarly, longer exposure to mechanical ventilation within lower tidal volume (10 mg/kg, five hours) caused lung injury including bronchial epithelial apoptosis. Hydrogen improved gas exchange and reduced VILI-induced apoptosis.
Inhaled hydrogen gas effectively reduced VILI-associated inflammatory responses, at both a local and systemic level, via its antioxidant, anti-inflammatory and antiapoptotic effects.
Although ventilatory support is often required in the intensive care unit (ICU) for the treatment of critically ill patients with respiratory failure (including acute respiratory distress syndrome, pneumonia, septic shock, trauma, aspiration of vomit, and chemical inhalation), mechanical ventilation (MV) itself can induce lung injury and worsen preexisting lung injury depending on the setting and the length of ventilation [1, 2]. This condition has been recognized as ventilator-induced lung injury (VILI). Despite recent progress in reducing the time on MV (for example, earlier weaning and extubation) and improving safety of MV (for example, lung protective ventilation with lower tidal volume), VILI remains a major concern in the ICU and can lead to remote organ dysfunction and multiple organ failure .
Multifactorial etiologies of VILI, from either direct or indirect injury to the lung, are postulated . MV with high tidal volumes and pressure can lead to increased alveolar-capillary permeability accompanied by the release of pro-inflammatory mediators by the lung cells in response to mechanical stretch. These stimuli trigger detachment of endothelial cells from the basement membrane and synthesis of extracellular matrix components [5, 6]. Injurious MV also promotes alveolar coagulopathy and fibrin deposition within the airways . In addition, generation of reactive oxygen species (ROS) during VILI causes direct cellular injury and triggers ROS-sensitive, aberrant activation of cellular mechanisms leading to severe inflammation, resulting in rapid transcription of pro-inflammatory cytokines and chemokines [8, 9].
Adjunctive therapy with inhaled therapeutic medical gas is promising and might be reasonable for lung disease as it would be an easily delivered and straightforward therapeutic option . Hydrogen, recently discovered to be a novel therapeutic medical gas in a variety of biomedical fields, has potent antioxidant and anti-inflammatory efficacies by eliminating toxic ROS [11–14]. However, to our knowledge, hydrogen therapy has not been tested in the VILI setting. Though highly flammable, hydrogen is safe in concentrations of less than 4.6% when mixed with air and at concentrations of less than 4.1% when mixed with oxygen . In this study, we investigated the hypothesis that, owing to its antioxidant and anti-inflammatory properties, inhaled hydrogen therapy could ameliorate VILI.
Materials and methods
Male wild-type C57BL6 mice (10 to 12 weeks old, 25 to 30 g) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All animals were maintained in laminar flow cages in a specific pathogen-free facility at the University of Pittsburgh. The experimental protocol was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh, and all experiments were performed in adherence to the National Institutes of Health guidelines for the use of laboratory animals.
Lung injury model
Mice were anesthetized by intraperitoneal injections of 85 mg/kg ketamine and 15 mg/kg xylazine. Then, under sterile conditions, a tracheostomy was performed with a 20-gauge angiocatheter which was sutured in place. Mice were placed in a supine position on a warming device and then connected to a ventilator (Harvard Apparatus, Holliston, MA, USA) on volume-control mode at a constant inspiratory flow. MV was initiated with a tidal volume of 30 mL/kg or 10 mL/kg (without an end-expiratory pressure) at a respiratory rate of 120 breaths per minute [16, 17]. Mean arterial blood pressure was continuously monitored via catheterization of a femoral artery by means of a blood pressure monitor (Cardiomax III; Columbus Instruments, Columbus, OH, USA). Mice received intravenous injection of 0.05 mL/hour saline as well as intraperitoneal ketamine and xylazine to maintain the blood pressure at 75 to 80 mm Hg. At the end of the experiment, the animal was euthanized with 150 mg/kg ketamine intraperitoneally.
Mice were randomly assigned to one of four experimental groups: MV (tidal volume 30 mL/kg, fraction of inspired oxygen [FiO2] 0.21, 2 hours) with 2% nitrogen in air (Praxair, Inc., Danbury, CT, USA), MV with 2% hydrogen in air (Praxair, Inc.), sham controls exposed to 2% nitrogen, or sham controls exposed to 2% hydrogen (n = 8 for each group). The concentration of 2% hydrogen was determined on the basis of previous observations as an optimal and safe concentration [11, 18]. Mice under ventilation received the therapeutic (2% hydrogen) or control (2% nitrogen) gases via the tracheal tube. Animals in the sham groups were given therapeutic gases for 2 hours by means of a gas chamber  and underwent anesthesia only prior to sacrifice and procurement of tissue. While under anesthesia, the control mice received hydrogen or nitrogen through a face mask by spontaneous respiration. In separate experiments, mice were subjected to MV with a lower tidal volume for a longer period (10 mL/kg, FiO2 0.21, 5 hours) with 2% nitrogen or hydrogen in air (n = 6 for each group). At sampling, after the right lung was isolated and tied off with a microclamp at the right bronchus, the left lung was used for bronchoalveolar lavage (BAL). The right lower lobe was used for wet-to-dry (W/D) ratio measurement, the right middle lobe was used for histologic examination, and the other portions of the right lung were immediately snap-frozen in liquid nitrogen for further experiments, including gene expression analyses.
The left lung was used for BAL via slow intratracheal injection of three sequential 0.5-mL aliquots of sterile normal NaCl. Cell pellets obtained by centrifuging BAL samples at 1,500 rpm for 5 minutes at 4°C were resuspended in 1 mL of phosphate-buffered saline. The cell viability was determined via trypan blue exclusion assay. In brief, 10 μL of cells was mixed with 10 μL of 0.4% trypan blue and loaded onto a hemocytometer. Protein concentration in the bronchoalveolar lavage fluid (BALF) was measured with bovine IgG as a standard as previously described .
Histopathological, immunohistochemistry, and TUNEL staining
For histologic evaluation, the right middle lobes of the lungs were fixed in 10% formalin, embedded in paraffin, sectioned to 6 μm in thickness, and stained with hematoxylin and eosin. The slides were blindly reviewed by one of the authors (NT) without knowledge of experimental groups (n = 6 for each group). Acute lung injury was scored according to the following four items: alveolar congestion, hemorrhage, infiltration or aggregation of neutrophils in the airspace or the vessel wall, and thickness of the alveolar wall/hyaline membrane formation . For analysis of macrophage infiltration, formalin-fixed, paraffin-embedded mouse lung sections (4 μm) were deparaffinized and underwent antigen unmasking with an appropriate buffer. After protein blocking (DakoCytomation, Carpinteria, CA, USA) for 15 minutes, rat anti-mouse F4/80 primary antibody (clone: CI:A3-1; AbD Serotec, Raleigh, NC, USA) was applied and incubated overnight at 4°C. After blocking endogenous peroxidase, biotinylated goat anti-rat secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) were applied followed by ABC Elite reagent (Vector Laboratories, Burlingame, CA, USA). Staining was developed with AEC chromogen (ScyTek Laboratories, Inc., Logan, UT, USA), and the tissue was counterstained with hematoxylin. The TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling) method was used for identification of bronchiolar cell apoptosis with the ApopTag Peroxidase Kit (Intergen Co., Purchase, NY, USA). TUNEL-positive bronchial epithelial cells in five random, high-power fields per section were counted with the samples' identities masked.
Arterial blood analysis
At the end of the experiment, arterial blood was obtained from the abdominal aorta. Blood gas analyses and measurement of lactate concentration were performed by means of an iSTAT handheld device (Abaxis, Union City, CA, USA).
Wet-to-dry weight ratio
The right lower lobe was weighed immediately after collection and placed into a 60°C oven to dry for 2 days. The dried tissue was weighed to determine the W/D weight ratio.
Real-time RT-PCR and tumor necrosis factor-alpha enzyme-linked immunosorbent assay
Since one of the underlying mechanisms of VILI is the release of pro-inflammatory mediators by the lung cells and airway epithelial cell apoptosis in response to mechanical stretch, quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) for inflammatory mediators was conducted on RNA extracted from the lung tissues. The mRNAs for early growth response-1 (Egr-1), chemokine (CC motif) ligand 2 (CCL2), interleukin (IL)-1β, tumor necrosis factor-alpha (TNFα), B-cell lymphoma-2 (Bcl-2), Bcl-xL (B-cell lymphoma-extra large), Bax (B-cell lymphoma-2-associated X-protein), and β-actin were quantified in duplicate by means of SYBR Green two-step, real-time RT-PCR as previously described . The levels of serum TNF-α were detected by specific enzyme-linked immunosorbent assay (Thermo Scientific, part of Thermo Fisher Scientific Inc., Waltham, MA, USA) in accordance with the manufacturer's protocol.
Oxidative injury from VILI was determined by measuring the tissue concentration of malondialdehyde (MDA), a marker of lipid peroxidation, by means of the MDA-586 kit (OxisResearch; Percipio Biosciences, Inc., Foster City, CA, USA) in accordance with the manufacturer's instructions.
Results are presented as mean ± standard deviation. The EZAnalyze add-in for Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) was used to perform analysis of variance with an F test and Bonferroni post hoc group comparisons. After the application of a log transformation to the data, Bartlett's test of homogeneity was not significant and comparison boxplots indicated that the assumption of constant variance was not violated. Nonetheless, in cases of possible heterogeneity, an analysis was performed on the log-transformed data. Histopathological score was analyzed with a Kruskal-Wallis test with post hoc Steel-Dwass test for group comparisons. A P value of less than 0.05 was considered statistically significant.
Lung injury after mechanical ventilation with high tidal volume
To evaluate the magnitude of lung injury by MV, sequential blood gas analysis of arterial blood from the mice exposed to 2% nitrogen via the ventilator was performed. Ventilator support improved gas exchange for the first 1 hour, while inhibition of gas exchange was seen in the animals at the beginning of MV because of muscle relaxation by general anesthesia. Subsequently, partial pressure of arterial oxygen (PaO2) gradually decreased with time in the ventilated mice and the partial pressure of arterial carbon dioxide (PaCO2) increased, suggesting that MV with high tidal volume provoked lung damage, related to alveolar overdistension or volutrauma, in a time-dependent manner (Figure 1a). To determine whether hydrogen inhalation affected hemodynamics, we monitored blood pressure and heart rate under MV. One hour after the start of MV, there was a significant decrease in mean arterial pressure in the mice ventilated with 30 mL/kg of tidal volume. There was no significant difference in hemodynamics between the VILI/N2 and VILI/H2 treatment groups over the 2-hour period. Inspiratory pressure was continuously monitored. Peak inspiratory pressure of the mice ventilated with 30 mL of tidal volume was 26.2 ± 0.7 cm H2O, which remained at constant levels throughout the experiment regardless of exposure to nitrogen or hydrogen.
Gas exchange during ventilator-induced lung injury
Although the effects of MV with either 2% nitrogen or 2% hydrogen in air using a tidal volume of 30 mL/kg for 30 minutes on lung function were negligible, VILI was induced by 2 hours of ventilation with 2% N2 in air with a tidal volume of 30 mL/kg, as indicated by a significant decrease in PaO2 and an increase in PaCO2. Ventilation with 2% hydrogen in air exerted protective effects on the lungs and improved oxygenation of the arterial blood (Figure 1b). There was no statistical difference in PaCO2 levels among the groups. The blood pH did not differ between the 30-minute and 2-hour time points nor did it differ between the treatment groups (VILI/N2 for 30 minutes, blood pH 7.25 ± 0.05; VILI/H2 for 30 minutes, pH 7.28 ± 0.06; VILI/N2 for 2 hours, pH 7.24 ± 0.04; and VILI/H2 for 2 hours, 7.25 ± 0.05).
Ventilator-induced lung injury-induced pulmonary edema
MV exacerbated pulmonary inflammation and injury, as indicated by thickening of the alveolar septum and infiltration of inflammatory cells, evident in histopathological examination. In the presence of hydrogen, both edema and inflammatory cell infiltration were reduced despite exposure to MV with a 30 mL/kg tidal volume (Figure 2a) and the lung injury score was significantly improved with hydrogen inhalation (Table 1). Two hours of MV with high tidal volume (2% N2 in air) significantly increased the lung W/D ratio compared with lungs of sham mice. Ventilation with 2% hydrogen in air ameliorated ventilator-induced edema, as indicated by a significant decrease in lung W/D ratio as compared with ventilation with 2% N2 in air (Figure 2b).
Lung lipid peroxidation
Although there were increased MDA-protein adducts in the lung ventilated with a high tidal volume of 2% nitrogen in air, ventilation with 2% hydrogen reduced tissue MDA levels after 2 hours of MV with high tidal volume (Figure 2c).
Alveolar-capillary leak due to ventilator-induced lung injury
MV with 30 mL/kg tidal volume caused an acute exudative phase with alveolar-capillary leak in conjunction with leukocyte extravasation and resulted in an increase in the total cell number in the BALF. The effects of hydrogen on total cells or protein concentration in the BALF were marginal (Figure 3a, b). While blood lactate levels increased in ventilated mice receiving 2% nitrogen, they did not increase in mechanically ventilated mice receiving 2% hydrogen in air (Figure 3c).
Expression of inflammatory mediators and apoptosis-related genes
VILI after ventilation with 2% nitrogen resulted in upregulation of mRNAs for Egr-1, TNFα, IL-1β, and CCL2. Hydrogen administration significantly attenuated the upregulation of the mRNAs for these inflammatory mediators (Figure 4). Hydrogen inhalation increased the expression of antiapoptotic genes, such as Bcl-2 and Bcl-xL, and reduced VILI-induced expression of the pro-apoptotic Bax gene (Figure 5). There was no significant difference in mRNA expression for the housekeeping gene β-actin among the groups (data not shown).
Ventilator-induced lung injury with lower tidal volume
Finally, we analyzed whether hydrogen therapy could also attenuate VILI induced using a less invasive protocol with longer exposure to MV of lower tidal volume. Inducing VILI in the mice via a tidal volume of 10 mL/kg for 5 hours resulted in deterioration of gas exchange in mice receiving 2% nitrogen with an associated increase in pulmonary edema. These lung injuries were significantly attenuated by treatment with 2% hydrogen (Figure 6a, b). Hydrogen treatment significantly reduced serum TNFα concentrations as compared with the serum levels of TNFα in mice with VILI caused by ventilation with 2% nitrogen (Figure 6c).
In this VILI model with lower tidal volume, hydrogen treatment significantly decreased macrophage infiltration, as determined by F4/80 staining, as compared with lungs ventilated with 2% nitrogen (Figure 7a, c). MV with 2% nitrogen also increased apoptotic cell death of bronchial epithelial cells, as determined by TUNEL. Ventilation with 2% hydrogen significantly reduced TUNEL-positive epithelial cells as compared with ventilation with 2% nitrogen (Figure 7b, c).
In this study, we demonstrated that administration of hydrogen gas mitigated VILI and VILI-associated oxidative and inflammatory responses as well as VILI-induced apoptotic cell death of bronchial epithelial cells. To our knowledge, this is the first study to demonstrate that hydrogen gas significantly reduces VILI. Since VILI is a major concern with intensive care, approaches to minimize VILI will advance critical care medicine and could have substantial clinical impact.
Recently, the biological functions of therapeutic gases have received considerable attention and hydrogen was identified as a physiologically relevant gaseous signaling molecule like other endogenously generated gases, including nitric oxide (NO), carbon monoxide, and hydrogen sulfide [22–24]. Thus, hydrogen has been described as 'the fourth signaling gaseous molecule' .
Hydrogen has great potential as a safe and potent therapeutic medical gas as well as several potential advantages as a therapeutic option for VILI. Inhalation therapy is a straightforward approach to lung disease and can be administered by simply providing gas for the patient to inhale. Hydrogen may be relatively easily incorporated into our current interventional or surgical procedures without increasing their complexity. Inhaled hydrogen gas has been safely used for treatment of decompression syndrome in divers , suggesting that hydrogen can be safely administered to patients. Hydrogen is a stable molecule and does not react with other therapeutic medical gases at room temperature and thus may be administered as a combined gas with other therapeutic gases or inhaled anesthesia agents . Hydrogen does not alter NO levels . Endogenous NO signaling pathways are critical for modulating pulmonary vascular tone and leukocyte/endothelial interactions; therefore, it may be beneficial to spare endogenous NO . Hydrogen treatment does not eliminate superoxide anion (O2-) or hydrogen peroxide (H2O2) . O2- and H2O2 have important functions in neutrophils and macrophages, allowing phagocytosis. Hydrogen therapy may spare the innate immune system, and this would be beneficial because lung infection accompanies VILI in many cases .
Importantly, experimental studies have demonstrated the protective effects of hydrogen for septic shock , brain injury , liver injury , ischemic heart disease , and paralytic ileus . As all of these diseases frequently coincide with VILI in ICU patients, inhaled hydrogen therapy by simply delivering the gas through the ventilator could be a very promising adjunctive therapy in the ICU or operating room.
In our study, hydrogen inhalation ameliorated upregulation of the mRNAs for TNFα, IL-1β, Egr-1, and CCL2 after 2 hours of MV, and this may explain the anti-inflammatory mechanisms afforded by hydrogen in this VILI model. Egr-1 acts as a key pro-inflammatory regulator in VILI. Hoetzel and colleagues  demonstrated that Egr-1-deficient mice did not sustain lung injury after ventilation, relative to wild-type mice. The CC chemokine family is essential for the leukocyte recruitment during inflammation. Mounting evidence suggests that CCL2, a member of the CC chemokine family, is involved in numerous inflammation disorders of the lung, including VILI . Pro-inflammatory cytokines, such as TNFα and IL-1β, are elevated and play pivotal roles during the pathogenesis of VILI .
In our model, the increase in W/D ratio because of MV was relatively mild, despite the larger changes observed in lung function (gas exchange). The histopathology changes were moderate. We are unsure of the reason for these discrepancies, although perhaps W/D ratio is a very sensitive method to detect lung edema and a small difference of W/D ratio may represent significant edema. The gravimetric measure of lung edema poses considerable technical challenges, including evaporative loss and regional heterogenesity. W/D can be complicated by the inclusion of blood in the wet lung weight from both residual intravascular blood and blood introduced into the lung interstitium via bleeding or injury . In addition, extravasated protein can contribute to total lung weight. Although there are mismatches in magnitude of lung injury depending on which parameter is evaluated, each evaluation is scientifically sound and each indicates some degree of VILI that was ameliorated by hydrogen treatment.
VILI has been shown to induce apoptosis of airway epithelial cells . We demonstrated, in the present study, that hydrogen could upregulate antiapoptotic genes, including Bcl-2 and Bcl-xL. Although our findings do not explain all of the mechanisms underlying the protective effects of hydrogen, we postulate that the Bcl-2/Bcl-xL pathway might be one of the key mechanisms. Additionally, cyclic stretch associated with high-tidal-volume MV generates ROS and redox imbalance in lung epithelial and endothelial cells . The antioxidant properties of hydrogen to eliminate ROS may contribute to the mitigation of VILI in our model.
In our blood gas analyses, there were no significant differences in PaCO2 levels between animals exposed to 2% nitrogen or 2% hydrogen, although MV for 2 hours significantly increased PaCO2 levels compared with MV for 30 minutes. These findings suggest that PaCO2 levels may not be the best therapeutic indicator in our model, although PaO2 levels are very sensitive indicators of the magnitude of VILI. Our ventilation protocol was based on maintaining PaCO2 in a range of 25 to 35 mm Hg during the first 30 minutes of the MV period. We acknowledge the limitations of using PaCO2 as a marker of VILI in our model; as a marker, PaCO2 would not be applicable for clinical use and may be influenced by auto-positive end-expiratory pressure, overdistension, or atelectasis; however, the PaCO2 changes observed in our study were likely caused by VILI and not by a poorly controlled MV setting.
PaCO2 levels can influence inflammation and edema of the lungs. Hypocapnia increases microvascular permeability and impairs alveolar fluid reabsorption, which may influence the pathogenesis of pulmonary edema . Furthermore, hypocapnia is directly injurious to lung parenchyma and worsens ischemia/reperfusion injury . Therefore, permissive hypercapnia has been proposed as a protective strategy during MV and contributes to the attenuation of lung inflammatory response and pulmonary edema [39–42], and the potential exists for an independent protective/pathological role of alterations in carbon dioxide tension in the context of VILI. However, the VILI model in this study was designed to be normocapnic, and our results demonstrated that higher PaCO2 levels were not associated with less lung inflammation or edema, suggesting no influence of PaCO2 levels in our VILI model.
A more comprehensive understanding of the pharmacokinetics, biology, and toxicity of hydrogen will certainly help us harness the protective potential of hydrogen gas prior to clinical application. Virtually all patients under ventilation receive oxygen, and, in particular, patients with pulmonary disease usually require high levels of oxygen. Although hydrogen, when present at concentrations of less than 4%, poses no risk of explosion in air and oxygen, safety is still a concern, and the desired concentration of hydrogen must be legitimately monitored and maintained with commercially available tools. In this study, no adverse events related to hydrogen were observed. We acknowledge that this experimental model, like most animal models, does not recapitulate all aspects of clinical VILI. However, it is a scientifically sound study using a model appropriate to address the hypothesis. These findings will serve as a springboard to further translational research. Although extensive studies on toxicity and safety are needed, hydrogen treatment of ventilated patients may be clinically feasible and would be easy to incorporate without alteration of interventional and surgical procedures.
This study demonstrated a novel anti-inflammatory, antioxidative, and antiapoptotic function of hydrogen that ameliorated MV-induced lung injury.
Hydrogen inhalation therapy at a safe concentration mitigated ventilator-induced lung injury in mice.
Hydrogen inhalation demonstrated potent antioxidant and anti-inflammatory effects in a mouse ventilator-induced lung injury model.
Hydrogen reduced ventilation-induced epithelial apoptosis by induction of antiapoptotic genes.
Adjunctive therapy with inhaled therapeutic medical gas is promising and might be reasonable for lung disease as it would be an easily delivered and straightforward therapeutic option.
Hydrogen treatment of ventilated patients may potentially yield a novel, clinically feasible therapy that would be easy to incorporate without alteration of interventional and surgical procedures.
bronchoalveolar lavage fluid
- Bax :
B-cell lymphoma-2-associated X-protein
- Bcl-2 :
- Bcl-xL :
B-cell lymphoma-extra large
chemokine (CC motif) ligand 2
early growth response-1
fraction of inspired oxygen
intensive care unit
partial pressure of arterial carbon dioxide
partial pressure of arterial oxygen
reactive oxygen species
reverse transcription-polymerase chain reaction
tumor necrosis factor-alpha
terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling
ventilator-induced lung injury
Esteban A, Ferguson ND, Meade MO, Frutos-Vivar F, Apezteguia C, Brochard L, Raymondos K, Nin N, Hurtado J, Tomicic V, Gonzalez M, Elizalde J, Nightingale P, Abroug F, Pelosi P, Arabi Y, Moreno R, Jibaja M, D'Empaire G, Sandi F, Matamis D, Montanez AM, Anzueto A: Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med 2008, 177: 170-177. 10.1164/rccm.200706-893OC
Tremblay LN, Slutsky AS: Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006, 32: 24-33. 10.1007/s00134-005-2817-8
Amato MB, Barbas CS, Medeiros DM, Magaldi RB, Schettino GP, Lorenzi-Filho G, Kairalla RA, Deheinzelin D, Munoz C, Oliveira R, Takagaki TY, Carvalho CR: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998, 338: 347-354. 10.1056/NEJM199802053380602
Dos Santos CC, Slutsky AS: Invited review: mechanisms of ventilator-induced lung injury: a perspective. J Appl Physiol 2000, 89: 1645-1655.
Al-Jamal R, Ludwig MS: Changes in proteoglycans and lung tissue mechanics during excessive mechanical ventilation in rats. Am J Physiol Lung Cell Mol Physiol 2001, 281: L1078-1087.
Dreyfuss D, Saumon G: Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 1998, 157: 294-323.
Choi G, Wolthuis EK, Bresser P, Levi M, van der Poll T, Dzoljic M, Vroom MB, Schultz MJ: Mechanical ventilation with lower tidal volumes and positive end-expiratory pressure prevents alveolar coagulation in patients without lung injury. Anesthesiology 2006, 105: 689-695. 10.1097/00000542-200610000-00013
Papaiahgari S, Yerrapureddy A, Reddy SR, Reddy NM, Dodd OJ, Crow MT, Grigoryev DN, Barnes K, Tuder RM, Yamamoto M, Kensler TW, Biswal S, Mitzner W, Hassoun PM, Reddy SP: Genetic and pharmacologic evidence links oxidative stress to ventilator-induced lung injury in mice. Am J Respir Crit Care Med 2007, 176: 1222-1235. 10.1164/rccm.200701-060OC
Lentsch AB, Czermak BJ, Bless NM, Van Rooijen N, Ward PA: Essential role of alveolar macrophages in intrapulmonary activation of NF-kappaB. Am J Respir Cell Mol Biol 1999, 20: 692-698.
Nakao A, Sugimoto R, Billiar TR, McCurry KR: Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009, 44: 1-13. 10.3164/jcbn.08-193R
Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, Ohta S: Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007, 13: 688-694. 10.1038/nm1577
Fukuda KI, Asoh S, Ishikawa M, Yamamoto Y, Ohsawa I, Ohta S: Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress. Biochem Biophys Res Commun 2007, 361: 670-674. 10.1016/j.bbrc.2007.07.088
Buchholz BM, Kaczorowski DJ, Sugimoto R, Yang R, Wang Y, Billiar TR, McCurry KR, Bauer AJ, Nakao A: Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury. Am J Transplant 2008, 8: 2015-2024. 10.1111/j.1600-6143.2008.02359.x
Huang C, Kawamura T, Toyoda Y, Nakao A: Recent advances in hydrogen research as a therapeutic medical gas. Free Rad Res 2010, 44: 971-982. 10.3109/10715762.2010.500328
National Aeronautics and Space Administration: Safety Standard for Hydrogen and Hydrogen Systems: Guidelines for Hydrogen System Design, Materials Selection, Operations Storage, and Transportation. Washington, DC Office of Safety and Mission Assurance; 2005.
Nin N, Lorente JA, Fernandez-Segoviano P, De Paula M, Ferruelo A, Esteban A: High-tidal volume ventilation aggravates sepsis-induced multiorgan dysfunction in a dexamethasone-inhibitable manner. Shock 2009, 31: 429-434. 10.1097/SHK.0b013e318188b720
Martinez-Caro L, Lorente JA, Marin-Corral J, Sanchez-Rodriguez C, Sanchez-Ferrer A, Nin N, Ferruelo A, de Paula M, Fernandez-Segoviano P, Barreiro E, Esteban A: Role of free radicals in vascular dysfunction induced by high tidal volume ventilation. Intensive Care Med 2009, 35: 1110-1119. 10.1007/s00134-009-1469-5
Nakao A, Kaczorowski DJ, Wang Y, Cardinal JS, Buchholz BM, Sugimoto R, Tobita K, Lee S, Toyoda Y, Billiar TR, McCurry KR: Amelioration of rat cardiac cold ischemia/reperfusion injury with inhaled hydrogen or carbon monoxide, or both. J Heart Lung Transplant 2010, 29: 544-553. 10.1016/j.healun.2009.10.011
Nakao A, Kimizuka K, Stolz DB, Neto JS, Kaizu T, Choi AM, Uchiyama T, Zuckerbraun BS, Nalesnik MA, Otterbein LE, Murase N: Carbon monoxide inhalation protects rat intestinal grafts from ischemia/reperfusion injury. Am J Pathol 2003, 163: 1587-1598.
Hoetzel A, Schmidt R, Vallbracht S, Goebel U, Dolinay T, Kim HP, Ifedigbo E, Ryter SW, Choi AM: Carbon monoxide prevents ventilator-induced lung injury via caveolin-1. Crit Care Med 2009, 37: 1708-1715. 10.1097/CCM.0b013e31819efa31
Imanaka H, Shimaoka M, Matsuura N, Nishimura M, Ohta N, Kiyono H: Ventilator-induced lung injury is associated with neutrophil infiltration, macrophage activation, and TGF-beta 1 mRNA upregulation in rat lungs. Anesth Analg 2001, 92: 428-436. 10.1097/00000539-200102000-00029
Faller S, Ryter SW, Choi AM, Loop T, Schmidt R, Hoetzel A: Inhaled hydrogen sulfide protects against ventilator-induced lung injury. Anesthesiology 2010, 113: 104-115. 10.1097/ALN.0b013e3181de7107
Cardinal JS, Zhan J, Wang Y, Sugimoto R, Tsung A, McCurry KR, Billiar TR, Nakao A: Oral hydrogen water prevents chronic allograft nephropathy in rats. Kidney Int 2010, 77: 101-109. 10.1038/ki.2009.421
Itoh T, Fujita Y, Ito M, Masuda A, Ohno K, Ichihara M, Kojima T, Nozawa Y, Ito M: Molecular hydrogen suppresses FcepsilonRI-mediated signal transduction and prevents degranulation of mast cells. Biochem Biophys Res Commun 2009, 389: 651-656. 10.1016/j.bbrc.2009.09.047
George JF, Agarwal A: Hydrogen: another gas with therapeutic potential. Kidney Int 2010, 77: 85-87. 10.1038/ki.2009.432
Abraini JH, Gardette-Chauffour MC, Martinez E, Rostain JC, Lemaire C: Psychophysiological reactions in humans during an open sea dive to 500 m with a hydrogen-helium-oxygen mixture. J Appl Physiol 1994, 76: 1113-1118.
Pinsky DJ, Naka Y, Chowdhury NC, Liao H, Oz MC, Michler RE, Kubaszewski E, Malinski T, Stern DM: The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci USA 1994, 91: 12086-12090. 10.1073/pnas.91.25.12086
Hudson LD, Milberg JA, Anardi D, Maunder RJ: Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995, 151: 293-301.
Xie K, Yu Y, Pei Y, Hou L, Chen S, Xiong L, Wang G: Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock 2010, 34: 90-97. 10.1097/SHK.0b013e3181def9aa
Hayashida K, Sano M, Ohsawa I, Shinmura K, Tamaki K, Kimura K, Endo J, Katayama T, Kawamura A, Kohsaka S, Makino S, Ohta S, Ogawa S, Fukuda K: Inhalation of hydrogen gas reduces infarct size in the rat model of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 2008, 373: 30-35. 10.1016/j.bbrc.2008.05.165
Hoetzel A, Dolinay T, Vallbracht S, Zhang Y, Kim HP, Ifedigbo E, Alber S, Kaynar AM, Schmidt R, Ryter SW, Choi AM: Carbon monoxide protects against ventilator-induced lung injury via PPAR-gamma and inhibition of Egr-1. Am J Respir Crit Care Med 2008, 177: 1223-1232. 10.1164/rccm.200708-1265OC
Hillman NH, Moss TJ, Kallapur SG, Bachurski C, Pillow JJ, Polglase GR, Nitsos I, Kramer BW, Jobe AH: Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep. Am J Respir Crit Care Med 2007, 176: 575-581. 10.1164/rccm.200701-051OC
Wilson MR, Choudhury S, Takata M: Pulmonary inflammation induced by high-stretch ventilation is mediated by tumor necrosis factor signaling in mice. Am J Physiol Lung Cell Mol Physiol 2005, 288: L599-607. 10.1152/ajplung.00304.2004
Parker JC, Townsley MI: Evaluation of lung injury in rats and mice. Am J Physiol Lung Cell Mol Physiol 2004, 286: L231-246. 10.1152/ajplung.00049.2003
Bem RA, van Woensel JB, Bos AP, Koski A, Farnand AW, Domachowske JB, Rosenberg HF, Martin TR, Matute-Bello G: Mechanical ventilation enhances lung inflammation and caspase activity in a model of mouse pneumovirus infection. Am J Physiol Lung Cell Mol Physiol 2009, 296: L46-56. 10.1152/ajplung.00467.2007
Chapman KE, Sinclair SE, Zhuang D, Hassid A, Desai LP, Waters CM: Cyclic mechanical strain increases reactive oxygen species production in pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2005, 289: L834-841. 10.1152/ajplung.00069.2005
Myrianthefs PM, Briva A, Lecuona E, Dumasius V, Rutschman DH, Ridge KM, Baltopoulos GJ, Sznajder JI: Hypocapnic but not metabolic alkalosis impairs alveolar fluid reabsorption. Am J Respir Crit Care Med 2005, 171: 1267-1271. 10.1164/rccm.200408-998OC
Laffey JG, Engelberts D, Kavanagh BP: Injurious effects of hypocapnic alkalosis in the isolated lung. Am J Respir Crit Care Med 2000, 162: 399-405.
De Smet HR, Bersten AD, Barr HA, Doyle IR: Hypercapnic acidosis modulates inflammation, lung mechanics, and edema in the isolated perfused lung. J Crit Care 2007, 22: 305-313. 10.1016/j.jcrc.2006.12.002
Ni Chonghaile M, Higgins B, Laffey JG: Permissive hypercapnia: role in protective lung ventilatory strategies. Curr Opin Crit Care 2005, 11: 56-62. 10.1097/00075198-200502000-00009
Curley G, Laffey JG, Kavanagh BP: Bench-to-bedside review: carbon dioxide. Crit Care 2010, 14: 220. 10.1186/cc8926
Costello J, Higgins B, Contreras M, Chonghaile MN, Hassett P, O'Toole D, Laffey JG: Hypercapnic acidosis attenuates shock and lung injury in early and prolonged systemic sepsis. Crit Care Med 2009, 37: 2412-2420. 10.1097/CCM.0b013e3181a385d3
We thank Lisa Chedwick, Kumiko Isse, and John Brumsfield for their excellent technical support. This research was funded by National Institutes of Health grants GM R37-44100 (to TRB) and HL102528-01 (to AN) and research funds of the Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center.
The authors declare that they have no competing interests.
C-SH initiated the experimental design, participated in animal study, and drafted the manuscript. TK and SL carried out the molecular genetic studies and participated in the sequence alignment. NS, TRB, and YT participated in study design and coordination and helped to draft the manuscript. NT contributed to histopathological analysis. BMB and JDK contributed to statistical analysis. AN provided the working hypothesis, designed the study, helped to conduct the research, and wrote the manuscript. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.